MedTrace Logo

Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy

NCT06317558 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 4000

Last updated 2024-07-03

No results posted yet for this study

Summary

The goal of this observational study is to evaluate the efficacy and long-term clinical outcomes of different neoadjuvant immunotherapies in non-small cell lung cancer (NSCLC) patients using the real-world data. The main questions it aims to answer are:

* What the best setting for immune checkpoint inhibitors as the neoadjuvant treatment?
* How to determine the subgroups of patients benefit from neoadjuvant immunotherapy? Participants will receive neoadjuvant immunotherapy the study will analyze the real-world data.

Conditions

Interventions

DRUG

Neoadjuvant immunotherapy

Immune checkpoint inhibitors are used as neoadjuvant settings for NSCLC patients.

DRUG

Other drugs for neoadjuvant treatment

Drugs other than immune checkpoint inhibitors are being used as a new adjuvant setting for patients with NSCLC.

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Shugeng Gao, MD · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2026-03-01
Completion
2034-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06317558 on ClinicalTrials.gov